Cook MyoSite, Inc.

Cook MyoSite, Inc. is an American regenerative medicine company headquartered in Pittsburgh, Pennsylvania, and a subsidiary of the Cook Group. Established in 2002, the company was founded on the belief that the human body has restorative potential and has since dedicated itself to making regenerative medicine a part of everyday medicine. Its core scientific focus is muscle cell technology: the isolation, culture, characterization, and therapeutic use of human skeletal muscle-derived cells. The company's lead investigational platform is iltamiocel, an autologous muscle-derived cell (AMDC) therapy that targets the causes of muscle dysfunction rather than only the symptoms. Cook MyoSite states that this platform is under investigation in leading clinical trials for various medical uses. Alongside its therapeutic development, the company operates a Custom Cell Solutions portfolio and a contract research services business, supplying highly characterized primary human skeletal muscle cells and related services to researchers around the world. Cook MyoSite's contract services include muscle and other adherent cell production (such as mesenchymal stem cells), cryopreservation at any scale, manufacturing process development, procurement and processing of muscle cells from specific donor populations, custom media formulations, and QC analytical testing and assay development. Its Pittsburgh facilities are equipped for phase-appropriate GMP cell manufacturing and are described as able to deliver cells of high quality and dependability to locations across the globe. As a subsidiary of the Cook Group, Cook MyoSite is part of a privately held, family-owned organization with a long history in medical devices and life sciences. The company positions itself as "the most trusted name in muscle cell technology," emphasizing more than two decades of clinical development, rigorous quality standards, and deep insight into muscle cell manufacturing, analysis, and culture. Its customers and partners include academic researchers, physicians, and companies seeking muscle cell expertise, products, and services.

Cook MyoSite, Inc. was established in 2002 as a subsidiary of the Cook Group, the privately held, family-owned medical device and life sciences organization. The company was founded to pioneer advancements in cellular technologies, driven by a belief in the human body's restorative abilities. From its base in Pittsburgh, Pennsylvania, Cook MyoSite focused specifically on muscle-derived cell technology, an area in which it has since accumulated more than two decades of experience. Over its first 20-plus years, the company built deep expertise in muscle cell manufacturing, analysis, and culture. This work led to the development and delivery of autologous muscle-derived cell (AMDC) technologies, which the company describes as now under investigation in leading clinical trials for various medical uses. The investigational iltamiocel platform represents the therapeutic side of this effort, targeting the causes of muscle dysfunction rather than only the symptoms. Parallel to its therapeutic development, Cook MyoSite expanded into research products and services. Its Custom Cell Solutions portfolio offers a comprehensive range of muscle cell technology services to researchers around the globe, including highly characterized primary human skeletal muscle cells. The company also provides contract research services such as muscle and other adherent cell production (for example, mesenchymal stem cells), cryopreservation at any scale, manufacturing process development, procurement and processing of muscle cells from specific donor populations, custom media formulations, and QC analytical testing and assay development. Cook MyoSite's Pittsburgh facilities are equipped to support phase-appropriate GMP cell manufacturing and are described as able to deliver cells of high quality and dependability to any location across the globe. The company maintains qualified equipment, instruments, and facility systems to support this work. It partners with researchers and companies worldwide, offering insights, products, and services to support research in human muscle cell applications. As of the available evidence, Cook MyoSite remains an active subsidiary of the Cook Group, continuing to pursue its mission of making regenerative medicine a part of everyday medicine and positioning itself as the most trusted name in muscle cell technology.

• 2002

  Cook MyoSite, Inc. is established as a subsidiary of the Cook Group to pioneer advancements in cellular technologies.

• Development and delivery of autologous muscle-derived cell (AMDC) technologies, now under investigation in leading clinical trials.

• Launch of the Custom Cell Solutions portfolio offering muscle cell technology services to researchers globally.

• Expansion into contract research services including cell manufacturing, analytical testing, and process development.

The most trusted name in muscle cell technology; making regenerative medicine a part of everyday medicine.

• iltamiocel

  Investigational autologous muscle-derived cell (AMDC) platform targeting the causes of muscle dysfunction.

• Custom Cell Solutions

  Portfolio of muscle cell technology services and highly characterized primary human skeletal muscle cells for researchers.

• Contract research services

  Cell manufacturing, cryopreservation, process development, custom media, and QC analytical testing.

1. 1Muscle Cell Technology | Cook MyoSitecookmyosite.com
2. 2Research Contract Services | Cook MyoSitecookmyosite.com
3. 3About Our Team | Cook MyoSitecookmyosite.com
4. 4Cook MyoSite, Inc. (United States) - Wikidatawikidata.org